Maravai LifeSciences 株価情報 (NASDAQ: MRVI)

最新ニュース Maravai LifeSciences (NASDAQ:MRVI) 株価情報

Maravai LifeSciences

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences Holdings Inc

Analysts' ratings for BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, a high estimate of $150.00, and a low estimate of $91.00. This upward trend is apparent, with the current average reflecting a 19.85% increase from the previous average price target of $106.41.
<img src="https://www.benzinga.com/files/images/story/2024/1731092443_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of BioNTech by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$122.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$124.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$136.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$145.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$131.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$125.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$96.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$113.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$91.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to BioNTech. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for BioNTech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of BioNTech's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BioNTech analyst ratings.</a>
<h2>Discovering BioNTech: A Closer Look</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>BioNTech's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining BioNTech's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.04% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: BioNTech's net margin excels beyond industry benchmarks, reaching 15.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BioNTech's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): BioNTech's ROA stands out, surpassing industry averages. With an impressive ROA of 0.89%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BNTX

What Analysts Are Saying About BioNTech Stock

WIIM

Galiano Gold shares are trading lower after the company reported worse-than-expected Q3 revenue results.

In the last three months, 13 analysts have published ratings on Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Permian Resources and provided 12-month price targets. The average target is $18.38, accompanied by a high estimate of $21.00 and a low estimate of $14.00. Highlighting a 6.94% decrease, the current average has fallen from the previous average price target of $19.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1731092433_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Permian Resources among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$19.00</td>
<td>-</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Permian Resources. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Permian Resources compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Permian Resources's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Permian Resources's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Permian Resources analyst ratings.</a>
<h2>About Permian Resources</h2>
Permian Resources Corp is an independent oil and natural gas company focused on generating outsized returns to stakeholders through the responsible acquisition, optimization and development of oil and liquids-rich natural gas assets. The Company's assets and operations are primarily concentrated in the core of the Permian Basin, and its properties consist of large, contiguous acreage blocks located in West Texas and New Mexico.
<h3>Permian Resources's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Permian Resources's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -2.45%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Permian Resources's net margin excels beyond industry benchmarks, reaching 31.79%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Permian Resources's ROE stands out, surpassing industry averages. With an impressive ROE of 4.46%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Permian Resources's ROA stands out, surpassing industry averages. With an impressive ROA of 2.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Permian Resources's debt-to-equity ratio is below the industry average. With a ratio of 0.48, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Permian Resources

Freeport-McMoRan's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) short percent of float has risen 6.87% since its last report. The company recently reported that it has 24.41 million shares sold short, which is 1.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Freeport-McMoRan Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731092422_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Freeport-McMoRan has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Freeport-McMoRan's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Freeport-McMoRan's peer group average for short interest as a percentage of float is 3.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(FCX) - Analyzing Freeport-McMoRan's Short Interest

In the last three months, 13 analysts have published ratings on Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $46.69, a high estimate of $52.00, and a low estimate of $36.00. This current average has increased by 7.23% from the previous average price target of $43.54. 
<img src="https://www.benzinga.com/files/images/story/2024/1731092421_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Cheesecake Factory's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Katherine Griffin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$44.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Katherine Griffin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cheesecake Factory. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cheesecake Factory compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Cheesecake Factory's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Cheesecake Factory's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CAKE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cheesecake Factory analyst ratings.</a>
<h2>Discovering Cheesecake Factory: A Closer Look</h2>
Cheesecake Factory Inc owns and operates restaurants in the United States and Canada under brands that include The Cheesecake Factory, North Italia, and a collection within the Fox Restaurants Concepts subsidiary. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, other FRC, and Flower Child. Majority of the company's revenue comes from The Cheesecake Factory restaurants segment.
<h3>Understanding the Numbers: Cheesecake Factory's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Cheesecake Factory's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.25%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Cheesecake Factory's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.47%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 7.79%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Cheesecake Factory's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.03%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Cheesecake Factory's debt-to-equity ratio is below the industry average. With a ratio of 4.76, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAKE

What Analysts Are Saying About Cheesecake Factory Stock

Ulta Beauty's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NYSE">ULTA</a>) short percent of float has fallen 10.65% since its last report. The company recently reported that it has 2.06 million shares sold short, which is 5.62% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.02 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Ulta Beauty Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731092417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Ulta Beauty has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Ulta Beauty's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ulta Beauty's peer group average for short interest as a percentage of float is 12.81%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ULTA

Looking Into Ulta Beauty's Recent Short Interest

5 analysts have shared their evaluations of Coeur Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $7.95, with a high estimate of $8.50 and a low estimate of $7.00. This upward trend is evident, with the current average reflecting a 5.3% increase from the previous average price target of $7.55.
<img src="https://www.benzinga.com/files/images/story/2024/1731092412_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Coeur Mining. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dalton Baretto</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.75</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Kevin O'Halloran</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Brian MacArthur</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$6.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Coeur Mining. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Coeur Mining compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Coeur Mining's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Coeur Mining's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CDE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coeur Mining analyst ratings.</a>
<h2>Discovering Coeur Mining: A Closer Look</h2>
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
<h3>Financial Milestones: Coeur Mining's Journey</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Coeur Mining's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 61.1% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Coeur Mining's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 15.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.61%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.23%, the company showcases effective utilization of assets.
Debt Management: Coeur Mining's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.56, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Coeur Mining Stock: Analyst Perspectives (5 Ratings)

Welltower's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) short percent of float has fallen 22.32% since its last report. The company recently reported that it has 8.59 million shares sold short, which is 1.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Welltower Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731092411_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Welltower has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Welltower's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Welltower's peer group average for short interest as a percentage of float is 7.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

WELL

Looking Into Welltower's Recent Short Interest

Over the past 24 hours, Bittensor's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>) price has fallen 3.49% to $496.14. This is opposite to its positive trend over the past week where it has experienced a 7.0% gain, moving from $458.76 to its current price. 
The chart below compares the price movement and volatility for Bittensor over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092406_0.png" alt="price_chart" />
Bittensor's trading volume has climbed 10.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.08%. This brings the circulating supply to 7.38 million, which makes up an estimated 35.15% of its max supply of 21.00 million. According to our data, the current market cap ranking for TAO is #31 at $3.66 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092406_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Movers

$TAO

Cryptocurrency Bittensor Decreases More Than 3% Within 24 hours

<a href="https://x.com/IcebergResear/status/1854961131745690053">https://x.com/IcebergResear/status/1854961131745690053</a>
We are short Gevo Inc ($GEVO). The change in the US administration is the obvious threat but problems run deeper, in particular the competitiveness of technology. A lot of room to fall further.
In its last days, the Biden-driven Department of Energy has granted conditional approval for a $1.46b loan to Gevo, aimed at building a plant to produce alcohol-to-jet ("ATJ") aviation fuel.
Under a Trump-led administration, who called the IRA a "Green New Scam", Gevo's project is one of the most vulnerable DOE conditional approvals. The massive loan is subject to multiple conditions before approval, placing control in the hands of the DOE's new leadership.
Sustainable aviation fuels (SAF), whether HEFA or ATJ, are structurally more expensive than traditional jet fuel, and rely heavily on tax credits e.g. IRA and RFS. Generous IRA credits are now threatened and in any case, they expire in 2027.
ATJ (Gevo's type) is also more expensive than HEFA, the most common type of SAF (see above). Bulls argue HEFA will face future feedstock supply constraints (e.g. used oil), hence the need for ATJ.
The EU has mandated 6% SAF use by 2030, but even when the rule is implemented, current and incoming HEFA production will more than cover demand.
In the US, the DOE believes that HEFA won't cover SAF needs in 2030. But the DOE has assumed SAF would account for 12% (3b gal) of all fuel usage (25b gal) even though SAF adoption will be voluntary in the US, while Europe's 6% is mandatory.
Hard to believe that US airlines would voluntarily use twice more SAF than their European peers while airline margins are notoriously thin. Assuming 6% usage, in line with the EU in 2030, we found that expected US HEFA capacity (1.7b) will cover SAF needs (1.5b gal).
Worse, the electrification of vehicles will reduce the usage of renewable diesel, which shares the same feedstock as HEFA. This would release HEFA supply in favour of SAF. Another issue is that the EU bans crop-based biofuels like corn. Corn is Gevo's primary feedstock.
The track record of operators is crucial for a project as large as Gevo's ATJ plant. Gevo is known to have a history of under-delivering on promises. In 2019 for example, management unveiled plans to achieve $63-$77m of revenue in 2021. Actual revenue for the year was $0.5m.
Since 2013, the company has burnt through $678m of cash, and raised $887m in common equity. Share count has grown about 16x since 2019. Still, top managers received very attractive compensation packages despite this poor performance.
We believe the shifting political landscape and the challenging economics of ATJ make Gevo's renewable project highly speculative and prone to failure.

News

GEVO

Iceberg Research Posts On X "We are short Gevo Inc ($GEVO). The change in the US administration is the obvious threat but problems run deeper, in particular the competitiveness of technology. A lot of room to fall further."

HC Wainwright &amp; Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) with a Buy and maintains $5 price target.

Price Target

Reiteration

BRNS

HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target

Barclays analyst Brandt Montour maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Equal-Weight and raises the price target from $74 to $97.

Barclays Maintains Equal-Weight on Marriott Vacations, Raises Price Target to $97

Needham analyst Ryan Koontz reiterates Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) with a Buy and maintains $50 price target.

CLFD

Needham Reiterates Buy on Clearfield, Maintains $50 Price Target

RingCentral shares are trading lower following Q3 financial results.

Barclays analyst Tom O'Malley maintains MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) with a Overweight and raises the price target from $120 to $160.

MTSI

Barclays Maintains Overweight on MACOM Technology Solns, Raises Price Target to $160

CVR Energy shares are trading higher after Icahn Enterprises proposed a tender offer to acquire up to 15 million additional shares of CVR Energy common stock at $17.50 per share.

Barclays analyst Ross Sandler maintains Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) with a Equal-Weight and raises the price target from $14 to $20.

LYFT

Barclays Maintains Equal-Weight on Lyft, Raises Price Target to $20

Kevin O&#8217;Leary, known for his <a href="https://www.benzinga.com/startups/24/11/41781866/kevin-oleary-claims-you-have-to-work-25-hours-a-day-for-him-business-is-simple-you-either-make-money">straightforward views on business and investing</a>, recently weighed in on the Democratic Party's trajectory during an <a href="https://www.youtube.com/watch?v=OJL6LYMQfeo">appearance</a> on Fox News. And his take might surprise you – he thinks losing the upcoming election could be the best thing that happens to the Democrats.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Losing tonight is the best thing that could have happened to the Democratic Party. They circumvented democracy by anointing a candidate and suggested policies that went against the American dream. Losing the election should reset and reboot the Democratic party back to the center <a href="https://t.co/CUFQ9thaR7">pic.twitter.com/CUFQ9thaR7</a>
&mdash; Kevin O&#39;Leary aka Mr. Wonderful (@kevinolearytv) <a href="https://twitter.com/kevinolearytv/status/1854139515452916077?ref_src=twsrc%5Etfw">November 6, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before closing date.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>
O&#8217;Leary compared the current situation to a Super Bowl game, calling the presidential race &#8220;the Super Bowl of global politics.&#8221; <a href="https://www.benzinga.com/news/24/08/40541886/kevin-oleary-cautions-democrats-about-kamala-harris-they-did-the-same-thing-with-hillary-clinton">He criticized the Democrats</a> for &#8220;anointing&#8221; a candidate instead of allowing a proper process. &#8220;You don't bring a quarterback in that's never, ever, ever won any game anywhere,&#8221; he said, pointing out that President Biden, their &#8220;quarterback,&#8221; is currently struggling. Yet, the party didn't run a proper selection process for an alternative.
In his view, a loss would force the Democrats to &#8220;reset and reboot and get that party back to the center.&#8221; He argued that influential figures like Chuck Schumer, <a href="https://www.benzinga.com/startups/24/11/41714647/nancy-pelosi-claims-trump-will-double-down-on-tariffs-and-benefits-for-donors-she-warns-these-moves">Nancy Pelosi</a> and even Barack Obama won't be able to exert the same level of control four years from now, which could be a positive shift for the party and the country.
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
O&#8217;Leary also touched on some policy issues that he feels are misaligned with the American dream, particularly those concerning economic freedom. As an investor, he said he has to <a href="https://www.benzinga.com/news/24/09/40866546/as-an-investor-i-have-to-work-with-whoever-is-in-the-white-house-kevin-oleary-remarks-having-receive">work with whoever is in the White House</a>, but he can&#8217;t ignore policies that harm the core of what makes America unique. &#8220;All I do is work with entrepreneurs that want to build businesses,&#8221; he said, calling out two major policies: taxing unrealized capital gains and implementing price controls.
&#8220;That&#8217;s not America,&#8221; O&#8217;Leary declared. He clarified that taxing unrealized capital gains – requiring individuals to pay taxes on investments that haven&#8217;t even been sold – violates core American principles.&nbsp;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
He also criticized the idea of a higher corporate tax rate, which he believes would make the U.S. less competitive globally. &#8220;An 18% tax rate takes us to the bottom quartile of competition – that&#8217;s bad.&#8221; He believes measures like these deter innovation and investment, which are critical to economic expansion.
Despite his strong words, O&#8217;Leary made it clear that he respects <a href="https://www.benzinga.com/general/politics/24/11/41790636/kamala-harris-concedes-calls-for-unity-commitment-to-democracy">Vice President Kamala Harris</a> for her efforts in reaching where she is today. He thinks a defeat could give the party a much-needed chance to reconsider its course and return to emphasizing policies promoting development and opportunity.
&#8220;This could be great for America,&#8221; O&#8217;Leary said, stressing that a more centrist, pragmatic Democratic Party would benefit the entire country.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in 2 weeks.</a></li>
</ul>

Startups

Kevin O'Leary Says Losing Could Be The Greatest Moment For Democrats. Unrealized Capital Gains Taxes And Price Controls? 'Not America'

Barclays analyst Ryan Macwilliams maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Equal-Weight and raises the price target from $500 to $650.

HUBS

Barclays Maintains Equal-Weight on HubSpot, Raises Price Target to $650

Northland Capital Markets analyst Mike Grondahl maintains OppFi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) with a Outperform and raises the price target from $6 to $8.

OPFI

Northland Capital Markets Maintains Outperform on OppFi, Raises Price Target to $8

PGIM Jennison Health Sciences Fund Q2 2024 Commentary

In a report released on September 6, Brandon Couillard from Wells Fargo maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research R...

Maravai Lifesciences Holdings (MRVI) Gets a Buy from Wells Fargo

Codexis licenses Genomics Life Science enzyme portfolio to Alphazyme LLC

RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on October 23 and set a price ...

RBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)

Reports Q3 revenue $65.2M, consensus $67.55M. "We achieved significant milestones this quarter, launching innovative new products across the portfo...

Maravai Lifesciences reports Q3 adjusted EPS (2c), consensus (1c)

Consensus $275.55M. The company said, "Maravai's financial guidance for the full year 2024 is based on expectations for its existing business and d...

Maravai Lifesciences lowers FY24 revenue view to $255M-$265M from $265M-$285M

RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) today and set a price target o...

RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)

RBC Capital lowered the firm's price target on Maravai Lifesciences (MRVI) to $13 from $17 and keeps an Outperform rating on the shares after its w...

Maravai Lifesciences price target lowered to $13 from $17 at RBC Capital

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Eyes are on Nvidia (NVDA) during its f...

Nvidia trades on Dow for first time, Rivian reports downbeat Q3: Morning Buzz

Maravai LifeSciences stock plunges 39% amid lowered revenue forecast

ABBV

ABNB

AMGN

AMZN

APLS

ARGX

BBWI

BLMN

CABA

CDXS

DKNG

DOCS

EXPE

INDI

INOD

ISRG

MRNS

MRVI

NVDA

PAAA

PFRL

PHYL

PINS

PJFG

PJIO

PMIO

PRCH

PSDM

PTRB

PULS

RIVN

RVNC

SHOO

STLA

TOST

UPST

VRTX

Press Releases

Maravai Lifesciences Releases 2023 Environmental, Social and Governance (ESG) Report

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, August 7, 2024

Management

Maravai LifeSciences Appoints Trey Martin to Board of Directors

Earnings

Maravai LifeSciences Reports Second Quarter 2024 Financial Results

Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule

Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification Kits

TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase

Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024

Maravai LifeSciences Reports Third Quarter 2024 Financial Results

Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research

Agilent Technologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

RBC Capital

Baird

Goldman Sachs

Wells Fargo

Morgan Stanley

Maravai LifeSciences shares are trading lower after the company reported worse-than-expected Q3 financial results and cut its FY24 sales guidance. Additionally, William Blair downgraded the stock from Outperform to Market Perform and Baird cut its price target from $10 to $9.

Comments

Maravai LifeSciences

ニュース

最新ニュース Maravai LifeSciences (NASDAQ:MRVI) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル